Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat ...

Fintel reports that on July 14, 2025, BTIG downgraded their outlook for TechnipFMC (NYSE:FTI) from Buy to Neutral. Analyst ...

Fintel reports that on July 14, 2025, BTIG upgraded their outlook for Synchrony Financial (NYSE:SYF) from Neutral to Buy.

As of Monday, the S&P 500 has been trading above its 20-day moving average for 55 days. That's the longest stretch since ...

I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision ...

BTIG downgraded AFRM to "neutral" from "buy" Though shares of buy-now-pay-later name Affirm Holdings Inc (NASDAQ:AFRM) have ...

BTIG upgraded Synchrony Financial (SYF) and Bread Financial (BFH) to Buy, Ally Financial (ALLY) to Neutral and downgraded ...

Billionaire Kerr Neilson has bought over $8 million worth of shares in Flutter Entertainment plc (NYSE:FLUT), representing ...

Brokerage firm BTIG LLC accused StoneX Group Inc., a rival brokerage and investment bank, of stealing its proprietary software code in what its lawyers describe as “one of the greatest financial ...

Detailed price information for Tripadvisor Inc (TRIP-Q) from The Globe and Mail including charting and trades.

BTIG analyst Jeet Mukherjee initiated coverage of Arvinas (ARVN) with a Buy rating and $69 price target The company’s lead program, vepdegestrant, is a potent ER degrader for being developed for ...

U.S. brokerage firm BTIG on Monday sued rival StoneX Group Inc in San Francisco, accusing it of stealing trade secrets and seeking at least $200 million in damages.